Novel Detection System for Lung Cancer Curative Effect Monitoring
NCT02666755 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 160
Last updated 2016-01-29
Summary
The purpose of this study is to investigate the sensitivity，specificity and concordance rate of EGFR testing results in plasma in comparison of results in matched tumor tissues tested by amplification refractory mutation system(ARMS). Moreover, the investigators correlate our findings in plasma with survival of advanced patients.
Conditions
- Lung Neoplasms
Sponsors & Collaborators
-
Jian Zhang
lead OTHER
Principal Investigators
-
Jian Zhang, Doctor · Xijing Hospital
Eligibility
- Min Age
- 18 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-01-31
- Primary Completion
- 2018-01-31
- Completion
- 2018-04-30
More Related Trials
-
ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage I NSCLS by NGS
NCT03172156 ·Status: COMPLETED
-
Development and Application of Molecular Evaluation Instrument for Lung Cancer Diagnosis and Treatment
NCT06086587 ·Status: NOT_YET_RECRUITING
-
Feasibility of Intratumoral Washing Fluid for Detecting EGFR Mutations in Lung Cancer
NCT05517083 ·Status: COMPLETED ·Phase: NA
-
Practical Usability of EGFR Mutation Detection in ctDNA From Resectable NSCLC
NCT04922073 ·Status: UNKNOWN
-
Correlation Between EGFR Mutation Using cfDNAs and Circulating Tumor Cells in Patients With NSCLC
NCT02422628 ·Status: UNKNOWN
-
Analysis of Plasma Tumor DNA in Lung Cancer Patients
NCT01930474 ·Status: UNKNOWN
-
Identifying Genomic Mutations of Multiple Primary Lung Cancers by Circulating Tumor DNA
NCT02833467 ·Status: UNKNOWN
-
Analysis of Driver Gene Mutation in Early Stage Non-small Cell Lung Cancer
NCT04266691 ·Status: COMPLETED
-
A Comprehensive Evaluation of Circulating Tumor DNA and Circulating Tumor Cells as a Predictive Marker in Lung Cancer
NCT04254497 ·Status: COMPLETED
-
Construction and Evaluation of the Liquid Biopsy-based Early Diagnostic Model for Lung Cancer
NCT04156360 ·Status: UNKNOWN
-
Liquid Biopsy for Detection of Driver Mutation in NSCLC
NCT02778854 ·Status: UNKNOWN
-
Prediction of Targeted Therapy Efficacy in EGFR-mutant Lung Cancer Patients Using AI-based Multimodal Data
NCT07287904 ·Status: NOT_YET_RECRUITING
-
Multi-omics Study of Early-stage Lung Cancer With Distinct Phenotypes
NCT06699979 ·Status: RECRUITING
-
Non-Invasive ctDNA Methylation Detection for Lung Nodule Patients
NCT03685669 ·Status: UNKNOWN
-
A Study of the Gene Mutation Status in Cerebrospinal Fluid, Blood and Tumor Tissue of Non-small Cell Lung Cancer Patients With Brain Metastases
NCT03257735 ·Status: UNKNOWN
-
Multicenter Observational Study of Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Rare Driver Gene Mutation
NCT04137718 ·Status: UNKNOWN
-
A Study of Real-world Treatment Patterns and Outcomes in Chinese Advanced NSCLC Patients Who Previously Received at Least 2 Line Treatments
NCT06617390 ·Status: COMPLETED
-
Effects of Different Genetic Mutations on Prognosis in sMPLC Adenocarcinoma Patients
NCT03764371 ·Status: UNKNOWN
-
Liquid Biopsy in Advanced Oligometastatic NSCLC Receiving Surgery
NCT05648370 ·Status: UNKNOWN
-
A Multi-center Prospective Observational Biomarker Study on EGFRm+ Non-small Cell Lung Cancer Patients With Leptomeningeal Metastasis
NCT02803619 ·Status: UNKNOWN
-
Gene Mutations in Non-Small Cell Lung Cancer Cells
NCT00977509 ·Status: UNKNOWN
-
To Evaluate the Correlation Between the Results of Specific Gene Testing and the Efficacy of Targeted Therapy in Patients With NSCLC
NCT05805267 ·Status: COMPLETED
-
NGS-based Comprehensive Genomic ctDNA Panel in NSCLC With Immunotherapy
NCT04636047 ·Status: UNKNOWN
-
Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations
NCT05701787 ·Status: RECRUITING
-
SERS-Based Serum Molecular Spectral Detection of Invasive Lung Cancer
NCT06775015 ·Status: NOT_YET_RECRUITING